GTS Securities’s Franklin Genomic Advancements ETF HELX Stock Holding History

GTS Securities’s Portfolio HELX Stock Details HELX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-27,603	Closed	-$874K	–	4215
2024 Q2	$874K	Buy	27,603 +13,899	+101%	+$436K	﹤0.01%	2178
2024 Q1	$449K	Sell	13,704 -35,228	-72%	-$1.1M	﹤0.01%	2670
2023 Q4	$1.49M	Buy	+48,932	New	+$1.36M	﹤0.01%	1865
2023 Q3	–	Sell	-44,781	Closed	-$1.35M	–	4000
2023 Q2	$1.35M	Buy	+44,781	New	+$1.36M	0.04%	352

Other funds holding HELX

Glenview Trust Louisville, Kentucky $6.37B AUM 23.72% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

GTS Securities's HELX Position: Q3 2024 in Review

GTS Securities sold out of Franklin Genomic Advancements ETF (HELX) in Q3 2024, closing a stake of 27,603 shares — an estimated $874K sold.

GTS Securities first reported a position in HELX in Q2 2023 and held it in 4 quarters. The position peaked at $1.49M in Q4 2023. 5 funds tracked by Wall St. Rank hold HELX as of Q3 2024.

GTS Securities reported no remaining Franklin Genomic Advancements ETF position as of Q3 2024 after selling out during the quarter.
GTS Securities sold 27,603 Franklin Genomic Advancements ETF shares in Q3 2024, an estimated $874K.
GTS Securities first reported a position in Franklin Genomic Advancements ETF in Q2 2023 and held it in 4 quarters.
GTS Securities's Franklin Genomic Advancements ETF position peaked at $1.49M in Q4 2023.
5 funds tracked by Wall St. Rank held Franklin Genomic Advancements ETF as of Q3 2024.

Based on GTS Securities's 13F filing for Q3 2024, filed 13 Nov 2024.